NEW YORK, NY -- (Marketwire) -- 06/29/12 -- Shares of biotech companies in the anti-obesity market surged on the announcement that the Food and Drug Administration had approved the first weight loss pill since Roche Holding AG's Xenical in 1999. According to data from the National Institute of Health obesity related spending could rise to $343 billion in 2018. The Paragon Report examines investing opportunities in the Biotech Industry and provides equity research on Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Roche Holding Ltd. (PINKSHEETS: RHHBY).
Access to the full company reports can be found at:
Arena Pharmaceuticals anti-obesity drug Belviq was approved by the FDA on Wednesday. The drug was cleared for use in obese/overweight adults who have at least one medical condition. Obesity has become a major problem in the U.S. as it is estimated roughly 35 percent of the population is obese.
"The approval of this drug, used responsibly in combination with a healthy diet and lifestyle, provides a treatment option for Americans who are obese or are overweight and have at least one weight-related comorbid condition," said FDA's drug center director, Dr. Janet Woodcock, in a statement.
Paragon Report releases regular market updates on the Biotech Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.ParagonReport.com and get exclusive access to our numerous stock reports and industry newsletters.
Three double-blind, randomized, placebo-controlled trials demonstrated that Arena's Belviq along with diet and exercise was more effective than diet and exercise alone at helping patients lose 5% or more of their body weight after one year and managing the weight loss for up to two years. Shares of the company soared nearly 30 percent the day FDA's approval was announced.
Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. The company recently announced that the FDA approved Perjeta for people with HER2-positive metastatic breast cancer.
Paragon Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Paragon Report has not been compensated by any of the above-mentioned companies. We act as independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at:
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here